Pharmaceutical

Filter

Current filters:

None

Popular Filters

1 to 25 of 6959 results

Earnings at Pfizer tank but still just beat expectations

Earnings at Pfizer tank but still just beat expectations

29-07-2014

Taking the brunt of generic competition to former blockbuster drugs, US pharma giant Pfizer posted a…

FinancialPfizerPharmaceuticalUSA

Eli Lilly to establish production of insulin in Russia

Eli Lilly to establish production of insulin in Russia

29-07-2014

US pharma major Eli Lilly has reached an agreement with one of Russia’s leading drugmakers, R-Pharm,…

DiabetesEli LillyHumulin RInsulinPharmaceuticalProductionR-PharmRussia

Canada’s Health Minister moves on safe prescribing practices for drugs prone to abuse

Canada’s Health Minister moves on safe prescribing practices for drugs prone to abuse

29-07-2014

Canada’s Minister of Health, Rona Ambrose, has issued a national Call for Proposals to improve the…

CanadaNeurologicalPharmaceuticalRegulation

Recordati reports first half results with sales up 6.3%

Recordati reports first half results with sales up 6.3%

29-07-2014

Italian drugmaker Recordati saw its shares rise 2.1% to 12.30 euros after the company released first…

FinancialItalyPharmaceuticalRecordatiZanidip

PaxVax acquires the FDA-approved typhoid vaccine Vivotif

PaxVax acquires the FDA-approved typhoid vaccine Vivotif

29-07-2014

Privately-held California, USA-based specialty vaccine firm PaxVax says it has acquired the oral typhoid…

LicensingMergers & AcquisitionsPaxVaxPharmaceuticalProductionSwitzerlandVaccinesVivotif

Novartis’ Bexsero has high uptake in first widespread public vaccination program against meningitis B

Novartis’ Bexsero has high uptake in first widespread public vaccination program against meningitis B

29-07-2014

Swiss drug major Novartis has announced initial results from a large-scale vaccination campaign using…

Anti-viralsBexseroCanadaMeningitis BNovartisPharmaceuticalResearch

pSivida’s Iluvien given marketing authorization in Norway and reimbursement approval in Portugal

pSivida’s Iluvien given marketing authorization in Norway and reimbursement approval in Portugal

29-07-2014

Eye disease specialist pSivida has been granted marketing authorization in Norway for its treatment Iluvien,…

IluvienNorwayOphthalmicsPharmaceuticalPortugalpSividaRegulation

Executive Q&A: Thomas Hein, SVP commercial and regulatory affairs, Hermes Pharma

Executive Q&A: Thomas Hein, SVP commercial and regulatory affairs, Hermes Pharma

28-07-2014

In an interview with The Pharma Letter, Thomas Hein, senior vice president of commercial and regulatory…

Dosage formsDrug DeliveryGermanyHermes PharmaInterviewsPharmaceutical

Reckitt Benckiser to spin out pharma; GSK views Consumer options

Reckitt Benckiser to spin out pharma; GSK views Consumer options

28-07-2014

UK-based consumer goods giant Reckitt Benckiser plans to spin off its USA-based pharmaceutical business,…

FinancialGlaxoSmithKlineMergers & AcquisitionsNeurologicalPharmaceuticalReckitt BenckiserSuboxoneUK

Celsion announces updated overall survival data from study of its ThermoDox in liver cancer

Celsion announces updated overall survival data from study of its ThermoDox in liver cancer

28-07-2014

Biopharma company Celsion has announced updated results from its retrospective analysis of cancer therapy…

CelsionOncologyPharmaceuticalResearchThermoDoxUSA

Pharmaceuticals, a strategic sector for the UK government

Pharmaceuticals, a strategic sector for the UK government

28-07-2014

Britain’s pharmaceuticals sector, which includes AstraZeneca and GlaxoSmithKline, two drugmakers among…

AstraZenecaEconomy of the United KingdomFinancialGlaxoSmithKlineMarkets & MarketingPharmaceuticalResearchUK

Alcon’s Simbrinza approved for glaucoma in the EU

Alcon’s Simbrinza approved for glaucoma in the EU

28-07-2014

Eyecare specialist Alcon, a division of Swiss drug major Novartis, says its Simbrinza eye drops suspension…

AlconEuropeEuropean CommissionGlaucomaOphthalmicsPharmaceuticalRegulationSimbrinza

1 to 25 of 6959 results

Back to top